Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.11.12.20230508: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources ) assays: Complement activation assays: Neutralization assays: Live-imaging: 1×104 U2OS-ACE0-GFP-1-10 and 1×104 U2OS-ACE0-GFP-11 cells were plated overnight in each compartment of a μ-Dish35 mm Quad (Ibidi). U2OS-ACE0-GFP-11suggested: NoneSoftware and Algorithms Sentences Resources Images were analyzed using the FIJI software. FIJIsuggested: (Fiji, RRID:SCR_002285), Prism 8 (GraphPad Software) or RStudio Desktop 1.3.1093 GraphPadsuggested:…SciScore for 10.1101/2020.11.12.20230508: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources ) assays: Complement activation assays: Neutralization assays: Live-imaging: 1×104 U2OS-ACE0-GFP-1-10 and 1×104 U2OS-ACE0-GFP-11 cells were plated overnight in each compartment of a μ-Dish35 mm Quad (Ibidi). U2OS-ACE0-GFP-11suggested: NoneSoftware and Algorithms Sentences Resources Images were analyzed using the FIJI software. FIJIsuggested: (Fiji, RRID:SCR_002285), Prism 8 (GraphPad Software) or RStudio Desktop 1.3.1093 GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)RStudiosuggested: (RStudio, RRID:SCR_000432)For R analysis we used the following packages: corrplot (https://github.com/taiyun/corrplot), pheatmap (https://CRAN.R-project.org/package=pheatmap), factoextra and FactoMineR (https://CRAN.R-project.org/package=factoextra) and readxl (https://CRAN.R-project.org/package=readxl). FactoMineRsuggested: (FactoMineR, RRID:SCR_014602)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:One limitation of our study is the absence of information regarding the date of virus acquisition in asymptomatic individuals. However, both S and AS were sampled at the beginning of the epidemic in Northern France and were likely infected within a short time frame. Our results confirm and extend reports of decreased antibody titers in asymptomatic individuals (Long et al., 2020; Sekine et al., 2020), in which Fc-associated antibody functions were not analyzed. Another limitation is the lack of PCR confirmation for the asymptomatic and mildly symptomatic individuals. Our analysis is therefore restricted to individuals who have seroconverted. Moreover, the different groups were not all age matched. In our first group, the asymptomatic individuals, were as expected, younger than the symptomatic individuals. This was balanced in our second group, in which we selected symptomatic individuals to match the age of the asymptomatic group. It will be of interest to accurately determine the influence of age and other clinical and biological characteristics on the intensity and polyfunctionality of the antibody response. The levels of antibodies targeting other viruses, including two seasonal coronaviruses were similar in asymptomatic and symptomatic individuals, suggesting that these previous infections did not impact disease severity. One noticeable exception was a higher titer of anti-Flu antibodies in symptomatic persons. The reasons for this remain to be characterized, but a simple...
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04325646 Recruiting Sero-epidemiological Study of the SARS-CoV-2 Virus Responsib… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
